Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 24, 2019
Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel DiseasesAdam S Faye, Timothy Wen, Ashwin N Ananthakrishnan, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 25, 2021
Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant DisabilityMaia Kayal, Ryan C Ungaro, Alexa Riggs, et al.Inflammatory Bowel Diseases|October 13, 2018
Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficileDana J Lukin, Garrett Lawlor, David P Hudesman, et al.Alimentary Pharmacology & Therapeutics|January 22, 2019
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factorsManasi Agrawal, Shirley Cohen-Mekelburg, Maia Kayal, et al.BMC Medical Genetics|May 19, 2010
Evaluation of 6 candidate genes on chromosome 11q23 for coeliac disease susceptibility: a case control studyKaren Brophy, Anthony W Ryan, Graham Turner, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 15, 2019
Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel DiseasesJordan E Axelrad, Ahmad Bazarbashi, James Zhou, et al.The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.Journal of Crohn'S & Colitis|August 31, 2023
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label ExtensionSilvio Danese, Remo Panaccione, Maria T Abreu, et al.Inflammatory Bowel Diseases|November 22, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by AgeAdam S Faye, David T Rubin, Corey A Siegel, et al.The American Journal of Gastroenterology|October 3, 2022
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS ConsortiumAmanda M Johnson, Maria Barsky, Waseem Ahmed, et al.Pageof 3